NCT06545747
Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI
StatusActive, Not Recruiting
PhasePhase 3
SponsorSun Yat-sen University
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 22 words
- Enrollment closed, study ongoing
- Site details revised
- Notable Eligibility criteria expanded, about 9 wordsv3
Notable Enrollment target: 304 to 490v2 Show 4 more changesShow less
- Primary and study completion dates: Dec 31, 2027 to Jul 31, 2028
- Start date: Jan 1, 2024 to Aug 1, 2024
- Primary endpoints: 1 to 2
- Secondary endpoints: 5 to 4
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
treatment-related G2+ respiratory toxicity
Timeframe: Recorded from the enrollment to 1 year after the completion of hypo-RT or 3 months after the completion of consolidative immunotherapy
progression-free survival rate
Timeframe: 2-year
Secondary (4)
local control rate
overall survival rate
patient reported outcome assessed by QLQ-C30
patient reported outcome
Arms and interventions
MRI-based hypo-RTExperimental
Patients will receive split-course hypo-RT combined with concurrent chemotherapy and consolidative immunotherapy. The experimental arm will undergo adaptive dose-painting hypo-RT based on DCE-MRI.
CT-based hypo-RTActive comparator
Patients will receive split-course hypo-RT combined with concurrent chemotherapy and consolidative immunotherapy. The control arm will undergo hypo-RT based on CT.
Radiation: DCE-MRI based split-course hypo-RT, CT based split-course hypo-RT
Drugs: Concurrent chemotherapy, Consolidative immunotherapy
Sites
1 site in 1 country
- Sun Yat-sen University Cancer CenterGuangzhou, China